University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 9L-18-18

A Phase 4, open-label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno-occlusive disease

Type: Treatment
Phase: Phase IV
Status: Open to Accrual
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  George Yaghmour, M.D.
Other Trial Staff:  John Lee, D.M., Suraj Chandwani, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.